1155

Cies, Jeffrey J.; Moore, Wayne; Dickerman, Mindy; Small, Christine; Carella, Dominick; Shea, Paul; Parker, Jason

doi:10.1097/01.ccm.0000458622.54084.4e

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One case series [9] and six case reports [10][11][12][13][14][15] revealed the management experience of the EI/CI of MER in critically infected children. Lu et al [9] reported that 16 of 24 children with acute leukemia and agranulocytosis with nosocomial infections experienced clinical improvement upon undergoing the EI of MER (20 mg/kg/dose, q8 h, over 3 h).…”

Section: Observational Studiesmentioning

confidence: 99%

“…However, the patient died due to multiple organ failure. In addition, five case reports [11][12][13][14][15] showed that children with severe infections recovered when the dosages were increased or the mode of infusion was changed from STI to CI. Three cases [11,12,14] achieved a probability of target attainment (PTA) of 100% after adjustment.…”

Section: Observational Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Extended or Continuous Infusion of Carbapenems in Children with Severe Infections: A Systematic Review and Narrative Synthesis

et al. 2021

View full text Add to dashboard Cite

We systematically reviewed the efficacy and safety of an extended or continuous infusion (EI/CI) versus short-term infusion (STI) of carbapenems in children with severe infections. Databases, including PubMed, Embase, the Cochrane Library, Clinicaltrials.gov, China National Knowledge Infrastructure, WanFang Data, and SinoMed, were systematically searched from their inceptions to 10 August 2020, for all types of studies (such as randomized controlled trials (RCTs), retrospective studies, and pharmacokinetic or population pharmacokinetic (PK/PPK) studies) comparing EI/CI versus STI in children with severe infection. There was no limitation on language, and a manual search was also conducted. The data were screened, evaluated, extracted, and reviewed by two researchers independently. Quantitative (meta-analysis) or qualitative analyses of the included studies were performed. Twenty studies (including two RCTs, one case series, six case reports, and 11 PK/PPK studies) were included in this review (CRD42020162845). The RCTs’ quality evaluation results revealed a risk of selection and concealment bias. Qualitative analysis of RCTs demonstrated that, compared with STI, an EI (3 to 4 h) of meropenem in late-onset neonatal sepsis could improve the clinical effectiveness and microbial clearance rates, and reduce the rates of mortality; however, the differences in the incidence of other adverse events were not statistically significant. Retrospective studies showed that children undergoing an EI of meropenem experienced satisfactory clinical improvement. In addition, the results of the PK/PPK study showed that an EI (3 or 4 h)/CI of carbapenems in severely infected children was associated with a more satisfactory goal achievement rate (probability of target attainment) and a cumulative fraction of response than STI therapy. In summary, the EI/CI of carbapenems in children with severe infection has a relatively sufficient PK or pharmacodynamic (PD) basis and satisfactory efficacy and safety. However, due to the limited quantity and quality of studies, the EI/CI therapy should not be used routinely in severely infected children. This conclusion should be further verified by more high-quality controlled clinical trials or observational studies based on PK/PD theories.

show abstract